Atomoxetine in the treatment of attention deficit hyperactivity disorder

References

• American Psychiatric Association. Diagnostic and Stistical Manual of 114ntal Disoirlers. Fourth Edition, Text Revision (DSM-IV-TR).American Psychiatric Association, Washington DC, USA (2000).
   Google Scholar
• Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle. Arn. Acad. Child Adoles. Psychiatry 35, 409–432 (1996).
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T et al Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Arn. j Psychiatry 155,693–695 (1998).
   PubMed Web of Science ®Google Scholar
• Greenhill L. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc. Psychiatric Clin. North Am. 4(1), 123–168 (1995).
   Google Scholar
• Pliszka SR. Nonstimulant treatment of attention deficit hyperactivity disorder. CNS Spectrums 8(4), 253–258 (2003).
   PubMedGoogle Scholar
• ••Provides an excellent overview ofnonstimulant treatments for attention deficit hyperactivity disorder.
   Google Scholar
• Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention deficit hyperactivity disorder. Child Adolesc. Psychiatry Clin. N Am. 9(30), 605–646 (2000).
   Google Scholar
• Conners CK, Casat CD, Gualtieri CT et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. jAm. Acad. Child Adolesc. PTchiatry35, 1314–1321 (1996).
   PubMed Web of Science ®Google Scholar
• Wilens TE, Spencer TJ, Biederman J et al A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am. Psychiatry158, 282–288 (2001).
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc. Psychiatric Clin. N Am. 9(1), 77–97 (2000).
   Google Scholar
• Dupaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda M, McGoey K. Parent ratings of attention deficit disorder symptoms: factor structure and normative data. J. PTchopathol. Beh. Assess. 20, 83–102 (1998).
   Web of Science ®Google Scholar
• Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). MultiHealth Systems, NY, USA (1999).
   Google Scholar
• Spencer T, Biederman J, Heiligenstein J et al An open-label, dose ranging study of atomoxetine in children with attention deficit disorder. J. Child. Adolesc. Bychoparmacology11,251–265 (2001).
   PubMed Web of Science ®Google Scholar
• Kratochvil C, Heiligenstein J, Spencer T et al Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Amer Acad. Child Adolesc. Psychiatry 41(7), 776–784 (2002).
   Google Scholar
• •The only published study of atomoxetine and a stimulant.
   Google Scholar
• Spencer JT, Heiligenstein JH, Biederman J et al Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention deficit hyperactivity disorder. J. Clin. Psychiatry 63,1140–1147 (2002).
   Google Scholar
• ••Primary efficacy studies of atomoxetinein children.
   Google Scholar
• Michelson D, Panes D, Wernicke J et al Atomoxetine in the treatment of children with ADHD: a randomized, placebo-controlled dose response study. Pediatrics 108(5), 83 (2001).
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J et al Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am.Psychiatry 159,1896–1901(2002).
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T et al Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol. Psychiatry53, 112–120 (2003).
   PubMed Web of Science ®Google Scholar
• •Primary efficacy studies of atomoxetine in adults.
   Google Scholar
• Biederman J, Spencer T Attention deficit hyperactivity disorder as a noradrenergic disorder. Biol. Fiychtry 46, 1234–1242 (1999).
   PubMed Web of Science ®Google Scholar
• Plizska SR, McCracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. jAm. Acad. Child Adolesc. Psych. 35, 264–272 (1996).
   Google Scholar
• Bymaster FP, Katner JS, Nelson DL et al Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neumpsychophatmacology27(5), 699–711 (2002).
   PubMed Web of Science ®Google Scholar
• ••Investigation of the mechanism of actionof atomoxetine.
   Google Scholar
• Stahl SM. Neurotransmission of cognition: part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. j Clin. Psychiatry 64(2), 110–111 (2003).
   Google Scholar
• Eli Lilly & Co., Strattera®, Atomoxetine Package Insert. Eli Lilly & Co., Indianapolis, IN, USA (2003).
   Google Scholar
• Ring BJ, Gillespie J, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 respeconsible for atomoxetine metabolism. Drug- Metab. Dispos. 30,319-323(2002).
   Google Scholar
• Belle DJ, Ernest S, Sauer J, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. j Clin. Pharmaco1.42, 1219–1227 (2002).
   Google Scholar
• Michelson D, Kratochvil C, Newcorn J, Gao H. Atomoxetine for comorbid ADHD and affective symptoms. Scientific Proceedings of the Annual Meeting- of the American Acacemy of Child & Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, placebo, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Biol. PTchiatry67, 149–156 (2002).
   Google Scholar
• Heiligenstein JH, Spencer TJ, Faries DE et al. Efficacy of tomoxetine versus placebo in pediatric outpatients with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry NY, USA (2000).
   Google Scholar
• Biederman J, Heiligenstein J, Panes D et al Efficacy of atomoxetine versus placebo in school-age girls with attention deficit hyperactivity disorder. Pediatrics 6,110 (2002).
   Google Scholar
• Newcorn JH. Atomoxetine or three-times daily methylphenidate in children with ADHD. Scientific Proceedings of the American Academy of Child & Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Kemner JE, Starr HL, Ciccone PE, Lynch JM. OROS® MPH provides greater ADHD symptom improvement than atomoxetine. Scientific Proceedings of the Annual Meeting of the American Psychiatric Association, NY, USA (2004).
   Google Scholar
• Wigal S, McGough JJ, Posner K et al. Analog classroom study of amphetamine extended release and atomoxetine in youth with ADHD. Scientific Proceedings of the American fiychiatric Association, NY, USA (2004).
   Google Scholar
• Allen AJ, Milton DR, Michelson D et al Efficacy of atomoxetine treatment for adolescents with attention deficit hyperactivity disorder. Scientific Proceedings of the Annual Meeting- of the American Academy of Child & Adolescent fiychiatry Miami, FL, USA (2003).
   Google Scholar
• Weiss M, Tannock R, Kratochvil C et al Placebo controlled study of once-daily atomoxetine in the school setting. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Kratochvil CJ, Milton D, Vaughan B, Burke W, Jones D. Atomoxetine in the treatment of young children with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Bychiatry Miami, FL, USA (2003).
   Google Scholar
• Kelsey D, Sumner C, Casat C et al. Once-daily atomoxetine for ADHD including evening and morning behavioral assessment. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, USA (2003).
   Google Scholar
• Michelson D. Optimizing response for ADHD residual symptoms after usual atomoxetine treatment. Scientific Proceedings of the Annual Meeting- of the American Academy of Child & Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Thomason C, Gelowitz DL. Effects of long-term atomoxetine treatment for young children with ADHD. Scientific Proceedings of the American Psychiatric Association, NY, USA (2004).
   Google Scholar
• Wilens TE, Newcorn JH, Kratochvil CJ, Gelowitz DL, Thomason C Gao H. Longer-term treatment with atomoxetine in adolescents with ADHD. Scientific Proceedings of the American Psychiatric Association, NY, USA (2004).
   Google Scholar
• Allen AJ, McCracken J, Sallee F et al Improvement of ADHD by atomoxetine in children with tic disorders. Scientific Proceedings of the Annual Meeting of the American Academy of Child & Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Sumner C, Kelsey D, Sutton V et al. Atomoxetine versus placebo for treating pediatric nocturnal enuresis. Scientific Proceedings of the Annual Meeting- of the American Academy of Pediatrics, LA, USA (2003).
   Google Scholar
• Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. j Clin. Psychiatry 63\(Suppl. 12), 50–55 (2002).
   Google Scholar
• •Summary of safety data from several atomoxetine pediatric trials.
   Google Scholar
• Wernicke JF, Adler L, Spencer T et al Changes in the symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. j Clin. PTchopharmacol 24(1), 30–35 (2004).
   PubMedGoogle Scholar
• Wernicke JF, Fades D, Girod D et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 26(10), 729–740 (2003).
   PubMedGoogle Scholar
• Adler L, Spencer T, Sutton V, Jones D, Sumner CR. Dose and time response of atomoxetine use in adult ADHD. Scientific Proceedings of the Annual Meeting- of the American Academy of Child and Adolescent Psychiatry Miami, FL, USA (2003).
   Google Scholar
• Adler L, Spencer T, Reimherr F, Michelson D, Jones D, Milton D. Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. Scientific Proceedings of the Annual Meeting- of the American PTchiatric Association, CA, USA (2003).
   Google Scholar